Last deal

$9.2M
Local Amount - CHF 8.5M

Amount

Series B

Stage

20.12.2022

Date

9

all rounds

$16.5M

Total amount

General

About Company
Resilell offers a diagnostic device that quickly determines the most effective antibiotic treatment for patients.

Industry

Sector :

Subsector :

founded date

01.01.2018

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

Founded in 2017 and based in Muttenz, Switzerland, Resistell has developed a diagnostic device that provides an alternative to culture-based antibiograms. By detecting movement caused by living bacterial cells, the device can determine bacterial resistance to antibiotics and recommend the appropriate antibiotic and concentration for treatment. This growth-independent method reduces the time taken to get results from days to minutes, offering a rapid and accurate solution for antibiotic susceptibility testing.
Contacts